Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.6% – What’s Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN) fell 4.6% on Monday . The stock traded as low as $11.30 and last traded at $11.29. 152,152 shares were traded during mid-day trading, a decline of 91% from the average session volume of 1,673,524 shares. The stock had previously closed at $11.83.

Analyst Upgrades and Downgrades

DYN has been the topic of several recent analyst reports. JPMorgan Chase & Co. cut their price target on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st. BMO Capital Markets initiated coverage on shares of Dyne Therapeutics in a research report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price target on the stock. Scotiabank started coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price target on the stock. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, Piper Sandler cut their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $46.85.

Dyne Therapeutics Trading Down 1.5%

The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -3.27 and a beta of 1.19. The firm has a 50-day moving average of $10.36 and a 200 day moving average of $17.35.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). Equities research analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This trade represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 6,237 shares of company stock valued at $77,760 over the last quarter. Company insiders own 14.14% of the company’s stock.

Institutional Trading of Dyne Therapeutics

A number of institutional investors have recently bought and sold shares of DYN. Caitong International Asset Management Co. Ltd boosted its position in Dyne Therapeutics by 378.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock valued at $32,000 after purchasing an additional 2,446 shares during the last quarter. Quarry LP acquired a new stake in shares of Dyne Therapeutics in the first quarter worth about $47,000. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics in the fourth quarter worth about $50,000. KBC Group NV lifted its position in shares of Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after buying an additional 978 shares during the last quarter. Finally, E Fund Management Co. Ltd. lifted its position in shares of Dyne Therapeutics by 16.2% in the first quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company’s stock worth $144,000 after buying an additional 1,923 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.